Study Finds Exenatide Not Beneficial for Parkinson Disease
By Elana Gotkine HealthDay Reporter
FRIDAY, Feb. 7, 2025 -- The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, according to a study published online Feb. 4 in The Lancet.
Nirosen Vijiaratnam, M.D., from the University College London Queen Square Institute of Neurology, and colleagues conducted a phase 3, multicenter trial at six research hospitals in the United Kingdom involving patients aged 25 to 80 years with a diagnosis of Parkinson disease who were randomly assigned to receive extended-release exenatide 2 mg by subcutaneous pen injection once per week over 96 weeks or visually identical placebo (97 patients in each group).
The analyses included 92 patients in the exenatide group and 96 in the placebo group with at least one follow-up visit. The researchers found that the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale part III score, off dopaminergic medication at 96 weeks, increased (worsened) by a mean of 5.7 and 4.5 points in the exenatide and placebo groups, respectively (adjusted coefficient for the effect of exenatide, 0.92; 95 percent confidence interval, −1.56 to 3.39; P = 0.47). Nine and 11 participants in the exenatide and placebo groups, respectively, had at least one serious adverse event.
"The results of this trial are discordant with previous laboratory and epidemiology data and previous trial results," the authors write. "We aim to do further post-hoc analyses to try and explain the reasons for this inconsistency."
Several authors disclosed ties to biopharmaceutical companies. AstraZeneca provided exenatide for the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Hearing Impairment Tied to Higher Risk for New Parkinson Disease Diagnosis
TUESDAY, Jan. 21, 2025 -- Hearing impairment is a risk factor for incident Parkinson disease (PD), according to a study published online in the February issue of Parkinsonism and...
Multiple Penicillin Courses Linked to Modestly Lower Risk for Parkinson Disease
MONDAY, Nov. 4, 2024 -- Adults who have received multiple penicillin courses have a modestly lower risk for Parkinson disease (PD), according to a study published in the October...
FDA Approves Vyalev for Advanced Parkinson Disease
TUESDAY, Oct. 22, 2024 -- The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson disease (PD). Vyalev...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.